EPR Properties vs Pfizer Inc — how do they compare? EPR Properties trades at $60.61 (market cap $4.58B), while Pfizer Inc trades at $26.21 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 33.1× EPR Properties's market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.
| EPR | PFE | |
|---|---|---|
Market Cap | $4.58B | $151.73B |
Sector | Real Estate | Health |
52-Week High | $64.32 | $28.56 |
52-Week Low | $48.71 | $23.60 |
Enterprise Value | $8.09B | $203.22B |
Dividend Yield | 6.22% | 6.46% |
Volume | — | 29,869,932 |
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $60.32, down 0.13% recently, with a bearish technical signal from moving averages and oscillators. The company reported strong Q2 2026 results, beating FFO estimates, and raised full-year guidance. Revenue grew to $699 million in 2026, though net income dipped to $263 million. Analysts maintain a consensus price target of $65.30, with 27% buy ratings, but technical indicators suggest near-term pressure.
The outlook is mixed: fundamental strength from dividend growth and acquisitions supports long-term value, but technical bearishness and elevated valuation ratios pose risks. Investors should weigh the 6% dividend yield against potential volatility from interest rate sensitivity and market sentiment shifts.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Trailing returns across standard periods
Latest headlines on both assets
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →